6 replies to this topic

[alc]

http://replicel.com/...-2017-forecast/

[Diocletian]

Finally some news from them I thought they were gone for good, 2018 sounds great if true, hurry up Replicel my hair can't wait.

[Izan]

their skin rejuvenation method also sounds highly interesting. turn back the clock 20 years!

[alc]

Finally some news from them I thought they were gone for good, 2018 sounds great if true, hurry up Replicel my hair can't wait.

 

"with respect to RCH-01 (pattern baldness), that: clinical data from a study being conducted in Japan, financed by Shiseido, is expected in 2018; the product has the potential to be launched in the Japanese market as soon as 2018"

 

I'm reserving some tickets to Tokyo ... lol

[niner]

I'd like to see Replicel succeed, but this paragraph from the above announcement is a bit of a concern:

 

 

In Japan, we are pleased Shiseido continues to fund the two-site clinical research study for pattern baldness (RCH-01). While our relationship continues to be troubled to the point of alleged breach and termination,  there has been no litigation, arbitration or other dispute resolution triggered. We continue to maintain our position that the agreement and relationship remains in good standing. Recent correspondence suggests the possibility of resuming discussions between the parties under certain conditions. We look forward to data from the Japanese RCH-01 (pattern baldness) study anticipated sometime in 2018 and continue to develop our own plans around the asset for markets outside Asia.

 

[alc]

A new interview with Lee Buckler:

 

"

 

RepliCel has four products in its pipeline.
Although treatments for Achilles Tendinosis and one for Pattern Baldness might seem miles apart, there is a logical connection.
Can you tell us about that?


We are working in three very different clinical indications – skin rejuvenation, pattern baldness, and chronic tendon injury.
The common thread is that the starting material for each is a single-stich biopsy of tissue taken from the back of the
patient’s scalp. In this tissue are two different cell populations that we isolate, grow, and manufacture into a product
delivered back to the clinic for injection. The one cell population is a cell that is responsible for hair growth
which – at the back of the scalp – is immune to androgenic alopecia. The other cell population is a cell that is
highly expressive of the types of proteins that build and maintain tissue – particularly Type 1 collagen which is
critically important to the structure of the extracellular matrix under your skin and the composition of your tendons.
Each of the conditions we treat are local conditions tied to the fact that the resident cells are not functioning as
intended. With an injection of news cells into the region, we can accomplish the kind of regrowth you just can’t
accomplish with surgery, drugs, or other biologics.

 

"

 

"

 

Can you tell us a bit about your partnership with Shiseido on RCH-01, your treatment for pattern baldness?
Shiseido is multi-billion dollar cosmetics and hair care company.
What kind of commitment has it made to RCH-01?

 

The deal with Shiseido gives them exclusive market rights to that product for Asia.
They paid $4-million upfront for that license and are committed to up to $31M in milestone payments
as they launch the product in various countries in their territory.
They are also committed to paying us single-digit sales royalties on every product sale in their markets.
Additionally this is a co-development deal in which they are financially committed to pay the direct costs
(in their territory) of clinical research/trials, manufacturing, regulatory approvals, sales, marketing and distribution.

 

"

 

 

 

"RepliCel CEO Lee Buckler talks to Cantech Letter"

 

http://www.cantechle...cantech-letter/

[alc]

 

I'd like to see Replicel succeed, but this paragraph from the above announcement is a bit of a concern:

 

 

In Japan, we are pleased Shiseido continues to fund the two-site clinical research study for pattern baldness (RCH-01). While our relationship continues to be troubled to the point of alleged breach and termination,  there has been no litigation, arbitration or other dispute resolution triggered. We continue to maintain our position that the agreement and relationship remains in good standing. Recent correspondence suggests the possibility of resuming discussions between the parties under certain conditions. We look forward to data from the Japanese RCH-01 (pattern baldness) study anticipated sometime in 2018 and continue to develop our own plans around the asset for markets outside Asia.

 

 

Lee Buckler heard about your concern(s) and addressed that here:

 

https://medicalresea...herapies/34087/

 

(he did not mention your name, but I'm sure it's in response to what you post often with "concerns" with everything that is NOT coming from sens direction):

 

 

"

 

MedicalResearch.com:

What recommendations do you have for future research as a result of this study?

Response:

For our product related to pattern baldness, we are pleased Shiseido continues
to fund the two-site clinical research study for pattern baldness (RCH-01).
Concurrently, we’re doing some exciting research and development on the
product (e.g., genetic expression studies) which we are confident will lead
to a significantly superior product that we looking forward to moving into
next-phase clinical testing. For our products related to skin rejuvenation
and tendon regeneration, we are now designing next-phase clinical studies
and in discussion with potential partners about potential collaborations.
These studies will focus on optimizing dose and treatment frequency.
In parallel we’re working on product development initiatives focused on
maximizing commercial viability of our products.

 

"